Neurogen Biomarking has announced a collaboration with American TelePhysicians’ venture NeuroX to support patients’ journey on its brain health care ecosystem, which expedites access to early Alzheimer’s dementia and mild cognitive impairment (MCI) detection technology.
Neurogen is offering virtual neurology services in this regard.
Go deeper with GlobalData
This collaboration aims to transform the early identification of Alzheimer’s disease (AD) via accessible blood biomarker testing and AI-powered digital assessments.
NeuroX’s neurologists will provide support to suitable patients of Neurogen through telehealth, offering follow-up care and expediting cognitive care access.
This service claims to significantly minimise the wait times often associated with traditional neurology care, offering assistance within weeks.
Neurogen noted that its Biomarking online platform includes Linus Health’s digital cognitive assessments to detect individuals at high risk of AD.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataEligible individuals receive a blood biomarker collection test, with guidance provided by a phlebotomist at home.
The collected blood sample is then analysed for phosphorylated tau at threonine 217 (ptau217), a key marker for AD pathology, at a certified laboratory.
NeuroX telehealth neurologists will support subjects through the Neurogen journey, providing services such as interpreting blood biomarker test outcomes, delivering brain health reports, and creating tailored action plans to enhance lifestyle factors like diet, sleep, and exercise.
The partnership extends through the Neurogen Diamond Network, which connects practice groups and academic centres nationwide, integrating with NeuroX’s telehealth neurologists.
Neurogen’s collaboration with NeuroX is complemented by partnerships with Linus Health for digital cognitive assessments and Quanterix Corporation for ultrasensitive biomarker identification.
The platform is set to become commercially available this year for individuals with suitable memory and thinking concerns.
Neurogen Biomarking founder and CEO Dr Rany Aburashed said: “Neurogen’s partnership with NeuroX is helping us achieve our goal to reimagine the patient journey for early detection of AD and MCI.
“Our partnership with NeuroX enhances our ability to shift that paradigm bringing their board-certified neurologists with specialised training in the nuances of early AD detection testing to everyone eligible so that they receive the highest level of cognitive care through Neurogen’s ecosystem.”
